EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S.)

Emanuela Palmerini iD, Peter Reichardt, Kirsten Sundby Hall, Rossella Bertulli, Stefan S Bielack iD, Alessandro Comandone, Gerlinde Egerer, Anna Hansmeier, Matthias Kevric, Elisa Carretta, Lina Hansson, Nina Jebsen und 6 weitere

Cancer · 2023

DOI: 10.1002/cncr.34964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Emanuela Palmerini und 17 weiteren Autor:innen. Beteiligte Einrichtung: Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Hauptthemen laut MEDLINE: Sarcoma, Osteosarcoma, Bone Neoplasms, Leiomyosarcoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rare primary malignant bone sarcomas (RPMBS) account for 5%–10% of primary high‐grade bone tumors and represent a major treatment challenge. The outcome of patients with RPMBS enrolled in the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S) is presented.

Methods

Inclusion criteria were as follows: age from 41 to 65 years and a diagnosis of high‐grade spindle cell, pleomorphic, or vascular RPMBS. The chemotherapy regimen included doxorubicin 60 mg/m 2 , ifosfamide 9 g/m 2 , and cisplatin 90 mg/m 2 ; postoperative methotrexate 8 g/m 2 was added in case of a poor histologic response. Version 2.0 of the Common Terminology Criteria for Adverse Events, Kaplan–Meier curves, log‐rank tests, and univariate Cox regression models were used.

Results

In total, 113 patients were evaluable for analysis. The median patient age was 52 years (range, 40–66 years), and 67 patients were men. Eighty‐eight tumors were categorized as undifferentiated pleomorphic sarcomas (UPS), 20 were categorized as leiomyosarcomas, three were categorized as fibrosarcomas, and two were categorized as angiosarcomas. Eighty‐three of 113 tumors were located in the extremities. Ninety‐five of 113 patients presented with no evidence of metastases. After a median follow‐up of 6.8 years (interquartile range [IQR], 3.5–9.8 years), the 5‐year overall survival rate for patients with localized disease was 68.4% (IQR, 56.9%–77.5%), and it was 71.7% (IQR, 58.1%–81.6%) for patients with UPS and 54.9% (IQR, 29.5%–74.5%) for patients with leiomyosarcoma. Grade III–IV hematologic toxicity was reported in 81% patients; 23% had grade II–III neurotoxicity, and 37.5% had grade I–II nephrotoxicity. Five‐year overall survival was significantly better for patients with localized disease, for patients who obtained surgical complete remission, and when the primary tumor was located in the extremities.

Conclusions

The survival of patients who had RPMBS in the current series was similar to that of age‐matched patients who had high‐grade osteosarcoma treated according to the same protocol. An osteosarcoma‐like chemotherapy may be proposed in patients who have RPMBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaOsteosarcomaBone NeoplasmsLeiomyosarcomaMaleHumansAdultMiddle AgedAgedFemaleAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDoxorubicinIfosfamide

Stichwörter der Autor:innen

angiosarcomabone sarcomachemotherapyfibrosarcomaleiomyosarcomamultimodality treatmentnonosteosarcoma malignant bone tumorsrare primary malignant bone sarcoma (RPMBS)ultra-rare sarcomaundifferentiated pleomorphic sarcoma

Substanzen

DoxorubicinIfosfamide

Autor:innen und Institutionen

  • Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Sarcoma Center, Helios Klinikum Berlin-Buch, Berlin, Germany.
  • Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Adult Mesenchymal Tumor Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Cooperative Osteosarcoma Study Group, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
  • SC Oncologia Azienda Sanitaria Locale "Città di Torino" Ospedale San Giovanni Bosco Torino, Turin, Italy.

ORCID-Profile: Emanuela Palmerini, Stefan S Bielack

Zitieren

APA

Palmerini, E., Reichardt, P., Hall, K. S., Bertulli, R., Bielack, S. S., Comandone, A., Egerer, G., Hansmeier, A., Kevric, M., Carretta, E., Hansson, L., Jebsen, N., Eriksson, M., Bruland, Ø. S., Donati, D. M., Ibrahim, T., Smeland, S., & Ferrari, S. (2023). Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S.). Cancer. https://doi.org/10.1002/cncr.34964

Vancouver

Palmerini E, Reichardt P, Hall KS, Bertulli R, Bielack SS, Comandone A, et al. Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S.). Cancer. 2023. doi:10.1002/cncr.34964

BibTeX
@article{Palmerini2023,
  author = {Palmerini, Emanuela and Reichardt, Peter and Hall, Kirsten Sundby and Bertulli, Rossella and Bielack, Stefan S and Comandone, Alessandro and Egerer, Gerlinde and Hansmeier, Anna and Kevric, Matthias and Carretta, Elisa and Hansson, Lina and Jebsen, Nina and Eriksson, Mikael and Bruland, Øyvind S and Donati, Davide Maria and Ibrahim, Toni and Smeland, Sigbjørn and Ferrari, Stefano},
  title = {Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S.)},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34964}
}
Kostenlos starten →